- Conditions
- Breast Cancer
- Interventions
- ARV-471, Anastrozole, Surgical resection of breast tumor
- Drug · Procedure
- Lead sponsor
- Arvinas Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 13
- States / cities
- Springdale, Arkansas • Los Angeles, California • Torrance, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- vepdegestrant, PF-07220060
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 34
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 22 more
- Conditions
- Advanced Breast Cancer
- Interventions
- ARV-471, Fulvestrant
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 624 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 87
- States / cities
- Encinitas, California • Fountain Valley, California • Fresno, California + 69 more
- Conditions
- Healthy
- Interventions
- single dose of vepdegestrant as tablet formulation (Treatment A), single dose of vepdegestrant as tablet formulation (Treatment B), single dose of vepdegestrant as tablet formulation (Treatment C)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Breast Cancer
- Interventions
- ARV-471, Abemaciclib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 23
- States / cities
- Palo Alto, California • San Francisco, California • Tampa, Florida + 11 more
- Conditions
- Healthy Participants
- Interventions
- vepdegestrant
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Miami, Florida • Miami Lakes, Florida • Orlando, Florida + 1 more
- Conditions
- Breast Cancer
- Interventions
- vepdegestrant, Samuraciclib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 19
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more
- Conditions
- Healthy
- Interventions
- vepdegestrant, esomeprazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- PF-07248144, Fulvestrant, Letrozole, Palbociclib, PF-07220060, PF-07850327, ARV-471, vepdegestrant
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 23
- States / cities
- Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 11 more
- Conditions
- Breast Cancer
- Interventions
- ARV-471, Ribociclib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 20
- States / cities
- Palo Alto, California • San Francisco, California • Tampa, Florida + 7 more
- Conditions
- Breast Cancer
- Interventions
- Vepdegestrant (ARV-471/PF-07850327), Palbociclib, Letrozole
- Drug · Combination Product
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Plantation, Florida • Norfolk, Virginia